Drug profile · INN
gemcitabine hydrochloride
GEMCITABINE HYDROCHLORIDE
gemcitabine hydrochloride (GEMCITABINE HYDROCHLORIDE) is a dna polymerase (alpha/delta/epsilon) inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Drug details — gemcitabine hydrochloride
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 8
- Data quality
- 0.89
Quick answer
gemcitabine hydrochloride (GEMCITABINE HYDROCHLORIDE) is a dna polymerase (alpha/delta/epsilon) inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA polymerase (alpha/delta/epsilon) inhibitor
Primary target: DNA polymerase (alpha/delta/epsilon)
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is gemcitabine hydrochloride?
gemcitabine hydrochloride (GEMCITABINE HYDROCHLORIDE) is a dna polymerase (alpha/delta/epsilon) inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
What is the brand name for gemcitabine hydrochloride?
GEMCITABINE HYDROCHLORIDE is a marketed brand name for gemcitabine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of gemcitabine hydrochloride?
gemcitabine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.